title: Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
abstract: The aim of this study was to perform a meta-analysis of currently available data regarding the prognostic significance of soluble suppression of tumorigenecity-2 (sST2) concentration in acute heart failure (AHF).
  
  
  
  Concentration of sST2 may have prognostic value in AHF. A comprehensive assessment of all available studies regarding sST2 in AHF is lacking.
  
  
  
  Three databases (MEDLINE, Cochrane Library, and Scopus) were searched. Inclusion criteria were follow-up studies, papers published in English, enrollment of patients with AHF, and availability of median hazard ratios for all-cause death and other outcome measures, when available.
  
  
  
  Ten studies were included, with a global population of 4,835 patients and a median follow-up duration of 13.5 months. The following global hazard ratios calculated for log2(sST2) were admission sST2 and all-cause death, 2.46 (95% confidence interval [CI]: 1.80 to 3.37; p < 0.001); discharge sST2 and all-cause death, 2.06 (95% CI: 1.37 to 3.11; p < 0.001); admission sST2 and cardiovascular death, 2.29 (95% CI: 1.41 to 3.73; p < 0.001); discharge sST2 and cardiovascular death, 2.20 (95% CI: 1.48 to 3.25; p < 0.001); admission sST2 and heart failure (HF) hospitalization, 1.21 (95% CI: 0.96 to 1.52; p = 0.060); discharge sST2 and HF hospitalization, 1.54 (95% CI: 1.03 to 2.32; p = 0.007); admission sST2 and all-cause death or HF hospitalization, 1.74 (95% CI: 1.24 to 2.45; p < 0.001); and discharge sST2 and all-cause death or HF hospitalization, 1.63 (95% CI: 1.14 to 2.33; p < 0.001).
  
  
  
  Plasma sST2 has prognostic value with respect to all-cause and cardiovascular death as well as the composite outcome of all-cause death or HF hospitalization, with both admission and discharge values having prognostic efficacy. Discharge sST2, but not admission sST2, is predictive of HF rehospitalization during follow-up.
authors.affiliation: Scuola Superiore Sant'Anna, Pisa, Italy. Electronic address: albertoaimo@libero.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Aimo
authors.affiliation: Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Toscana G. Monasterio, Pisa, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Vergaro
authors.affiliation: Fondazione Toscana G. Monasterio, Pisa, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Ripoli
authors.affiliation: Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.
authors.forename: Antoni
authors.initials: A
authors.lastname: Bayes-Genis
authors.affiliation: Hospital Universitario Arrixaca, University of Murcia, Murcia, Spain.
authors.forename: Domingo A
authors.initials: DA
authors.lastname: Pascual Figal
authors.affiliation: University Medical Center Groningen, Groningen, the Netherlands.
authors.forename: Rudolf A
authors.initials: RA
authors.lastname: de Boer
authors.affiliation: Heart and Lung Center, Helsinki University Hospital and Helsinki University, Helsinki, Finland.
authors.forename: Johan
authors.initials: J
authors.lastname: Lassus
authors.affiliation: INSERM U 942, Université Paris Diderot, APHP Hôpitaux Universitaires Saint Louis Lariboisière, Paris, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Mebazaa
authors.affiliation: INSERM U 942, Université Paris Diderot, APHP Hôpitaux Universitaires Saint Louis Lariboisière, Paris, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Gayat
authors.affiliation: Universitätsspital Basel, Basel, Switzerland.
authors.forename: Tobias
authors.initials: T
authors.lastname: Breidthardt
authors.affiliation: Universitätsspital Basel, Basel, Switzerland.
authors.forename: Zaid
authors.initials: Z
authors.lastname: Sabti
authors.affiliation: Universitätsspital Basel, Basel, Switzerland.
authors.forename: Christian
authors.initials: C
authors.lastname: Mueller
authors.affiliation: Department of Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands.
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Brunner-La Rocca
authors.affiliation: Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.
authors.forename: W H Wilson
authors.initials: WH
authors.lastname: Tang
authors.affiliation: Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
authors.forename: Justin L
authors.initials: JL
authors.lastname: Grodin
authors.affiliation: Peking Union Medical College, Beijing, China.
authors.forename: Yuhui
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: University of Porto Medical School, Porto, Portugal.
authors.forename: Paulo
authors.initials: P
authors.lastname: Bettencourt
authors.affiliation: University of California, San Diego, School of Medicine, San Diego, California.
authors.forename: Alan S
authors.initials: AS
authors.lastname: Maisel
authors.affiliation: Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Toscana G. Monasterio, Pisa, Italy.
authors.forename: Claudio
authors.initials: C
authors.lastname: Passino
authors.affiliation: Massachusetts General Hospital and Harvard Clinical Research Institute, Boston, Massachusetts.
authors.forename: James L
authors.initials: JL
authors.lastname: Januzzi
authors.affiliation: Scuola Superiore Sant'Anna, Pisa, Italy; Fondazione Toscana G. Monasterio, Pisa, Italy.
authors.forename: Michele
authors.initials: M
authors.lastname: Emdin
mesh_terms: D000208:Acute Disease; D002423:Cause of Death; D006333:Heart Failure / Q000097:blood*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D000072179:Interleukin-1 Receptor-Like 1 Protein / Q000097:blood*; D009026:Mortality; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: C079241:IL1RL1 protein, human; D000072179:Interleukin-1 Receptor-Like 1 Protein
keywords: acute heart failure; meta-analysis; prognosis; sST2